Stocks and Investing Stocks and Investing
Thu, October 25, 2018
Wed, October 24, 2018

Cory Kasimov Maintained (BIIB) at Buy with Decreased Target to $436 on, Oct 24th, 2018


Published on 2024-10-26 09:51:22 - WOPRAI, Cory Kasimov
  Print publication without navigation


Cory Kasimov of JP Morgan, Maintained "Biogen Inc." (BIIB) at Buy with Decreased Target from $445 to $436 on, Oct 24th, 2018.

Cory has made no other calls on BIIB in the last 4 months.



There are 9 other peers that have a rating on BIIB. Out of the 9 peers that are also analyzing BIIB, 3 agree with Cory's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Aaron Gal of "Bernstein" Downgraded from Buy to Hold on, Friday, October 19th, 2018
  • Geoff Meacham of "Barclays" Maintained at Hold with Increased Target to $320 on, Wednesday, July 25th, 2018
  • Brian Skorney of "Baird" Maintained at Hold with Increased Target to $348 on, Wednesday, July 25th, 2018


These are the ratings of the 6 analyists that currently disagree with Cory


  • Alethia Young of "Cantor Fitzgerald" Initiated at Buy and Held Target at $400 on, Monday, October 1st, 2018
  • Thomas Shrader of "Stifel" Initiated at Strong Buy and Held Target at $394 on, Tuesday, August 7th, 2018
  • Carter Gould of "UBS" Maintained at Strong Buy with Increased Target to $395 on, Thursday, July 26th, 2018
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $392 on, Wednesday, July 25th, 2018
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $396 on, Monday, July 23rd, 2018
  • Robyn Karnauskas of "Citigroup" Upgraded from Hold to Strong Buy and Held Target at $371 on, Friday, July 6th, 2018

Contributing Sources